Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy

Journal of Thoracic Oncology

Volumn 7, Issue 5, 2012, Pages 825-832

  Pataer, Apar ^a   Kalhor, Neda ^a   Correa, Arlene M ^a   Raso, Maria Gabriela ^a   Erasmus, Jeremy J ^a   Kim, Edward S ^a   Behrens, Carmen ^a   Lee, J Jack ^a   Roth, Jack A ^a   Stewart, David J ^a   Vaporciyan, Ara A ^a   Wistuba, Ignacio I ^a   Swisher, Stephen G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Histopathology; Lung cancer; Neoadjuvant chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; CANCER STAGING; CELL VIABILITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FIBROSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG TERM SURVIVAL; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NECROSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SURVIVAL PREDICTION; TREATMENT RESPONSE; TUMOR CELL;

EID: 84862141354     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318247504a     Document Type: Article

References (19)

1. American Cancer Society. Cancer Facts and Figures. Atlanta, GA: American Cancer Society, 2008. Available at: http://www.cancer.org/downloads/STT/ 2008CAFFfinalsecured.pdf. Accessed April 1, 2011.
2. Roth JA, Atkinson EN, Fossella F,. et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998;21:1-6.
3. Rosell R, Gomez-Codina J, Camps C,. et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized clinical trial. Lung Cancer 1999;26:7-14.
4. Pisters KM, Ginsberg RJ, Giroux DJ,. et al. Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg 2000;119:429-439.
5. Depierre A, Milleron B, Moro-Sibilot D,. et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002;20:247-253.
6. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 2009;36:260-271.
7. Song W-A, Zhou N-K, Wang W,. et al. Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer. An updated meta-analysis of 13 randomized control trials. J Thorac Oncol 2010;5:510-516.
8. Betticher DC, Schmitz S-F, Totsch M,. et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small cell lung cancer: a multicenter phase II trial. J Clin Oncol 2003;21:1752-1759.
9. Stefani A, Alifano, M, Bobbio A,. et al. Which patients should be operated on after induction chemotherapy for N2 non-small cell lung cancer? Analysis of a 7-year experience in 175 patients. J Thorac Cardiovasc Surg 2010;55:1-8.
10. Betticher DC, Schmitz S-F, Totsch M,. et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA p N2 non-small-cell lung cancer: 5 year follow-up of a phase II study. Br J Cancer 2006;94:1099-1106.
11. Poetten C, Theegarten D, Eberhardt W,. et al. Correlation of PET/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancer. Oncology 2007;73:316-323.
12. Junker K, Thomas M, Schulmann K,. et al. Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol 1997;123:469-477.
13. Junker K, Langner K, Klinke F,. et al. Grading of tumor regression in non-small cell lung cancer: morphology and prognosis. Chest 2001;120:1584-1591.
14. Liu-Jarin X, Stoopler MB, Raftopoulos H,. et al. Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy. Mod Pathol 2003;16:1102-1108.
15. Yamane Y, Ishii G, Goto K,. et al. A novel histopathological evaluation method predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy: the prognostic importance of the area of residual tumor. J Thorac Oncol 2010;5:49-55.
16. Herbst RS, Giaccone G, Schiller JH,. et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22:785-794.
17. Gatzemeier U, Pluzanska A, Szczesna A,. et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-1552.
18. Bepler G, Kusmartseva I, Sharma S,. et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006;24:4731-4737.
19. Ceppi P, Volante M, Novello S,. et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006;17:1818-1825.